公司研 究 证 券研究 报 告 其他化学制品Ⅲ 2024年5月1日 凯 赛生物（688065）2023年报及 2024年一季报点评 强 推 （维持） 目标价：61.75元 24Q1 业绩同环比修复，长链二元酸需求回暖 当前价：49.16元  事件：1）公司 2023 年实现营收 21.14 亿元，同比-13.39%；实现归母净利润 华创证券研究所 3.67亿元，同比-33.75%；实现扣非后净利润3.07亿元，同比-44.67%。其中， Q4 公司实现营收 5.49 亿元，同比/环比分别-9.07%/+2.55%；实现归母净利润 证券分析师：杨晖 0.53 亿元，同比/环比分别-21.5%/-26.9%。2）公司 2024Q1 实现营收 6.85 亿 邮箱：yanghui@hcyjs.com 元，同比/环比分别+35.4%/+24.8%；实现归母净利润 1.05 亿元，同比/环比 执业编号：S0360522050001 +83.4%/+100.0%。3）2023年度公司拟每10股派发现金红利1.90元（含税）， 现金分红共计1.10亿元。 证券分析师：郑轶  经营数据方面：1）产销数据：2023年公司长链 ...

公司研 究 证 券研究 报 告 其他化学制品Ⅲ 2024年5月1日 凯 赛生物（688065）2023年报及 2024年一季报点评 强 推 （维持） 目标价：61.75元 24Q1 业绩同环比修复，长链二元酸需求回暖 当前价：49.16元  事件：1）公司 2023 年实现营收 21.14 亿元，同比-13.39%；实现归母净利润 华创证券研究所 3.67亿元，同比-33.75%；实现扣非后净利润3.07亿元，同比-44.67%。其中， Q4 公司实现营收 5.49 亿元，同比/环比分别-9.07%/+2.55%；实现归母净利润 证券分析师：杨晖 0.53 亿元，同比/环比分别-21.5%/-26.9%。2）公司 2024Q1 实现营收 6.85 亿 邮箱：yanghui@hcyjs.com 元，同比/环比分别+35.4%/+24.8%；实现归母净利润 1.05 亿元，同比/环比 执业编号：S0360522050001 +83.4%/+100.0%。3）2023年度公司拟每10股派发现金红利1.90元（含税）， 现金分红共计1.10亿元。 证券分析师：郑轶  经营数据方面：1）产销数据：2023年公司长链 ...

“ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ “ ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ...

凯[Ta赛ble生_Sto物ckN（am6eR8p8tT0yp6e5] ） 公司研究/公司点评 一季度业绩大幅增长，生物基聚酰胺放量在即 投资评级：买入（维持） 主要观点： [Table_Rank] 报告日期： 2024-04-30 ⚫[ T事ab件le描_S述um mary] 2024年4月30日，凯赛生物发布了2023年年报及2024年一季报。 [收Ta盘bl价e_（Ba元se）D ata] 51.30 公司2023年实现营业收入21.14亿元，同比下降 13.39%；归母净利 近12个月最高/最低（元） 67.00/37.50 润3.67亿元，同比下降 33.75%，扣非归母净利润3.07亿元，同比下 总股本（百万股） 583 降44.67%。 流通股本（百万股） 583 2024年一季度实现营业收入6.85亿元，同比增长35.43%，环比增长 流通股比例（%） 100.00 24.76%；归母净利润1.05亿元，同比增长83.25%，环比增长99.96%， 总市值（亿元） 299 扣非归母净利润1.03亿元，同比增长100.99%，环比增长103.19%。 流通市值（亿元） 299 [公Ta司ble价 ...

大家介绍一下今年2003年年报和2024年一季报的一个情况大家可能还没有来得及详细的看我大致的介绍一下财务指标然后另外刘总刘博士还有其他的各位同事都在线上大家有什么问题我们可以在线上交流首先我介绍一下2023年度的财务数据和指标情况 23年公司实现营业收入是21.1亿元比上年同期下降13.39%实现毛利6.09亿从第22年下降29%实现营业利润是4.5亿元从低下降35%归属于上市公司股东的新利润是3.7亿比上年同期下降33.75% 这是23年年底总资产是188.3亿规模定资产是111.6亿去年研发投入是1.9亿研发投入占营收的比例为8.95%这个是23年的主要业绩情况那我接着再把今年一季度的业绩情况做一个介绍 今年一季度也就是2024年一季度的情况实现总的营业收入是6.8亿比上年从期上升35.43%环比24.4季度上升24.76%实现毛利1.96亿元比上年从期上升14%环比23年的四季度1.6亿环比上升了20% 今年一季度实现营业利润11.2亿 同比上升56% 环比上升121% 规模经营利润11.05亿 同比上升83% 环比四季度上升100% 截至2024年的一季度总资产是186亿归属于上市公司股东的净资产是 ...

凯赛生物2023年年报暨2024年一季报解读会_智能速览 2024年04月29日 23:39 关键词 营业收入 营业利润 净利润 研发投入 一季度业绩 毛利 生物制造 合成生物学 生物燃料 秸秆 生产资质审 批 生物基聚酯 新能源 光伏领域 双反政策 汽车轻量化 现代建筑 聚酰胺 生物机械 耐磨 全文摘要 凯塞生物展示了其在面对收入和毛利率下降的挑战时的经营策略和成果，通过加强产品研发和优化销售 策略成功实现了营业利润和净利润的增长。特别地，在2024年一季度实现了显著的增长，显示出了良好 的业务复苏迹象。凯塞生物也积极响应国家政策，聚焦生物制造领域，展现出了强劲的增长动力和广阔 市场前景。管理层对未来充满信心，并持续关注和执行政府政策，确立了生物制造作为公司的战略发展 方向。 讨论了凯瑟和招商局在生物制造领域的合作进展，包括成立联合工作小组和探索生物基尼龙材 料在太阳能、新能源等领域的应用，这表明两家公司正寻求通过政策支持共同促进产业的成长。同 时，双方都意识到了产业发展中存在的不确定性及挑战，如政策支持力度不足，强调了市场需求拓展的 重要性，并讨论了深化合作开发新应用场景的可能性。 中信证券和山西证券的代 ...

Revenue and Profit Growth - Revenue for Q1 2024 reached 684,521,536.95 RMB, a year-on-year increase of 35.43%[4] - Net profit attributable to shareholders of the listed company was 105,258,699.94 RMB, up 83.25% year-on-year[4] - Total operating revenue for Q1 2024 reached RMB 684.52 million, a 35.4% increase compared to RMB 505.45 million in Q1 2023[18] - Net profit attributable to parent company shareholders in Q1 2024 was RMB 105.26 million, up 83.3% from RMB 57.44 million in Q1 2023[19] - Basic earnings per share (EPS) for Q1 2024 were RMB 0.18, an 80% increase from RMB 0.10 in Q1 2023[20] - Basic and diluted earnings per share both increased by 80.00% to 0.18 RMB per share[8] R&D Investment - R&D investment totaled 44,784,258.67 RMB, a decrease of 9.89% year-on-year[4] - R&D investment as a percentage of revenue decreased by 3.29 percentage points to 6.54%[5] - R&D expenses in Q1 2024 decreased by 9.9% to RMB 44.78 million from RMB 49.70 million in Q1 2023[18] Cash Flow and Operating Activities - Net cash flow from operating activities surged to 215,276,527.96 RMB, a 171.65% increase compared to the same period last year[4] - Cash flow from operating activities in Q1 2024 was RMB 649.16 million, a 33.8% increase compared to RMB 485.11 million in Q1 2023[21] - Operating cash flow net amount: 215,276,527.96, an increase of 79,246,727.84 compared to the previous period[22] - Cash paid for goods and services in Q1 2024 was RMB 366.11 million, a 21.7% increase compared to RMB 300.90 million in Q1 2023[21] Assets and Liabilities - Total assets at the end of the reporting period were 18,617,743,763.23 RMB, a slight decrease of 1.14%[5] - Total assets decreased from RMB 18,833,372,759.88 to RMB 18,617,743,763.23, a decrease of approximately 1.15%[17] - Current assets decreased from RMB 7,570,668,208.85 to RMB 7,151,482,571.06, a decrease of approximately 5.53%[15] - Non-current assets increased from RMB 11,262,704,551.03 to RMB 11,466,261,192.17, an increase of approximately 1.81%[16] - Total liabilities decreased from RMB 4,060,262,557.16 to RMB 3,753,843,629.70, a decrease of approximately 7.55%[17] - Current liabilities decreased from RMB 3,409,752,675.79 to RMB 2,753,663,906.38, a decrease of approximately 19.24%[16] - Non-current liabilities increased from RMB 650,509,881.37 to RMB 1,000,179,723.32, an increase of approximately 53.76%[17] - Shareholders' equity increased from RMB 14,773,110,202.72 to RMB 14,863,900,133.53, an increase of approximately 0.61%[17] Cash and Cash Equivalents - Cash and cash equivalents decreased from RMB 5,390,218,174.98 to RMB 4,987,762,122.15, a decrease of approximately 7.47%[15] - Net increase in cash and cash equivalents: -218,561,556.52, an improvement of 156,098,219.90 compared to the previous period[22] - Ending cash and cash equivalents balance: 4,795,218,006.40, a decrease of 1,055,199,460.73 compared to the previous period[22] Accounts Receivable and Inventory - Accounts receivable increased from RMB 243,255,891.12 to RMB 291,690,168.89, an increase of approximately 19.91%[15] - Inventory decreased from RMB 1,466,355,603.97 to RMB 1,374,593,313.28, a decrease of approximately 6.26%[15] Operating Costs and Expenses - Operating costs for Q1 2024 were RMB 559.74 million, a 26.7% increase compared to RMB 441.82 million in Q1 2023[18] - Sales expenses in Q1 2024 were RMB 12.29 million, a slight 1.9% increase from RMB 12.07 million in Q1 2023[18] - Management expenses decreased by 33.6% to RMB 43.24 million in Q1 2024 from RMB 65.18 million in Q1 2023[18] Investment and Financing Activities - Cash outflow for investment activities: 463,229,410.48, a decrease of 23,865,493.07 compared to the previous period[22] - Cash inflow from financing activities: 728,258,447.26, an increase of 430,958,447.26 compared to the previous period[22] - Net cash flow from financing activities: 28,319,643.87, a decrease of 125,491,078.35 compared to the previous period[22] Government Subsidies and Non-Recurring Gains - Government subsidies contributed 3,143,696.20 RMB to non-recurring gains[6] Shareholder Information - The top shareholder, Cathay Industrial Biotech Ltd., holds 28.32% of the company's shares[9] Comprehensive Income - Total comprehensive income for Q1 2024 was RMB 104.78 million, a 49.2% increase from RMB 70.23 million in Q1 2023[19] Accounting Standards - The company did not apply new accounting standards or interpretations in 2024[23] Market Demand and Product Expansion - The company's long-chain dicarboxylic acid sales and revenue increased significantly due to market demand recovery and new product expansion[8]

Financial Performance - The net profit attributable to shareholders for 2023 was ¥366,524,351.34, with the parent company achieving a net profit of ¥3,865,342.75[5] - The company reported a revenue of RMB 1.5 billion for the fiscal year 2023, representing a year-over-year growth of 25%[12] - The company's operating revenue for 2023 was CNY 2,114,174,868.81, a decrease of 13.39% compared to CNY 2,441,103,971.54 in 2022[23] - Net profit attributable to shareholders for 2023 was CNY 366,524,351.34, down 33.75% from CNY 553,265,973.38 in 2022[25] - Basic earnings per share for 2023 was CNY 0.63, a decline of 33.68% compared to CNY 0.95 in 2022[24] - The gross margin improved to 45%, up from 40% in the previous year, due to operational efficiencies[12] - The company's total assets increased by 5.64% to CNY 18,833,372,759.88 at the end of 2023 from CNY 17,827,280,594.67 at the end of 2022[23] - The net cash flow from operating activities decreased by 29.14% to CNY 569,451,269.46 in 2023 from CNY 803,673,724.79 in 2022[25] Dividend Distribution - The company plans to distribute a cash dividend of ¥1.90 per 10 shares, resulting in a total cash dividend of ¥110,449,952.60 (including tax) based on the total share capital of 583,378,039 shares[5] - The cash dividend represents 38.73% of the net profit attributable to shareholders for the year[5] - The profit distribution policy requires approval from the board of directors and a majority vote from shareholders at the general meeting[200] - The company aims to distribute at least 10% of the annual distributable profit in cash after reserving statutory and surplus reserves[198] Business Expansion and Investments - The company announced a fundraising plan to raise no more than ¥6.6 billion to support business expansion in the field of bio-based materials[2] - Strategic investments were made in 2023, including a stake in the AI protein design platform company, Molecular Heart, and a joint venture agreement with 3P.COM focused on composite material design[2] - The company plans to raise up to 6.6 billion RMB through a private placement to support business expansion in the field of bio-based materials[35] - A strategic acquisition of a biotechnology firm was completed, enhancing the company's R&D capabilities and expected to contribute an additional RMB 100 million in revenue[12] Research and Development - Research and development expenses accounted for 8.95% of operating revenue in 2023, an increase of 1.26 percentage points from 7.69% in 2022[24] - The company emphasizes independent research and development, supported by collaborative efforts, focusing on synthetic biology and high-throughput research platforms[46] - The company is focused on enhancing its research capabilities in synthetic biology and aims to support the development of strategic emerging industries[49] - The company has invested RMB 300 million in new technology development focused on synthetic biology[12] Market Presence and User Growth - User data indicates an increase in active users by 30% compared to the previous year, reaching a total of 2 million active users[12] - The company is expanding its market presence in Southeast Asia, with plans to establish two new facilities by the end of 2024[12] - The company aims to enhance its market share by exploring industry consolidation opportunities and optimizing internal potential in response to potential market competition[65] Product Development and Innovation - The company has successfully completed pilot tests for its bio-based piperidine and is moving towards industrialization at a scale of 10,000 tons[2] - New product launches include a biomanufacturing platform expected to generate an additional RMB 200 million in revenue in 2024[12] - The company has developed a range of polyamides, including PA66 and PA6, which are widely used in various applications[15] - The company is developing bio-based polyamide thermoplastic composites reinforced with glass fiber and carbon fiber, which offer advantages such as lightweight, high strength, temperature resistance, and corrosion resistance, applicable in industries like new energy equipment and construction[42] Risk Management - The company is facing risks related to the loss of technical personnel, which could slow down R&D progress and impact competitive advantage[90] - There is a risk of core technology leakage, which could adversely affect the company's development and increase legal costs[91] - The company is exposed to raw material and energy price fluctuations, which could negatively impact operating performance if costs rise significantly[94] - The company faces risks from inventory devaluation, which could occur if market conditions lead to a significant drop in prices[99] Governance and Management - The company has a diverse board with members holding various positions, including independent directors and supervisors, ensuring governance and oversight[168] - The company has maintained a stable executive team with no significant changes in shareholding or compensation among key personnel[168] - The company emphasizes talent development by combining internal training with external recruitment to meet the demands of R&D and new projects[162] - The company has established a strong governance structure with significant shareholding by actual controllers and senior management[171] Sustainability and Environmental Commitment - The company aligns with national goals for carbon neutrality, aiming for a 13.5% reduction in energy consumption and an 18% reduction in carbon emissions per unit of GDP during the 14th Five-Year Plan period[49] - The company is committed to developing green low-carbon technologies and aims to establish a robust innovation ecosystem for bio-based materials by 2025[49] - The production of bio-based polyamide reduces carbon emissions by approximately 50% compared to traditional nylon 66 or nylon 6[86] Strategic Partnerships - The company has established long-term partnerships with major firms such as DuPont and Evonik, enhancing its market position[88] - The company has signed a business cooperation agreement with China Merchants Group to promote the use of bio-based polyamides in various sectors, including logistics and construction, enhancing sales and capacity utilization[149]

证券代码：688065 证券简称：凯赛生物 公告编号：2024-015 上海凯赛生物技术股份有限公司 关于持股 5%以上股东减持超过 1%的提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次权益变动不触及要约收购，不会导致公司控股股东及实际控制人发 生变化。 本次权益变动后，天津四通陇彤缘企业管理合伙企业（有限合伙）(以下 简称"天津四通")及其一致行动人 Seasource Holdings Limited(以下简称 "Seasource")持有上海凯赛生物技术股份有限公司（以下简称"公司"）股份 34,751,700 股，持股比例从 7.060%减少至 5.957%。 公司于 2024 年 4 月 22 日收到股东天津四通及 Seasource 出具的告知函，现 将其有关权益变动情况公告如下： | | 名称 1 | 天津四通陇彤缘企业管理合伙企业（有限合伙） | | --- | --- | --- | | 信息披 | 注册地址 | 天津自贸试验区（中心商务区）新华路 3678 号宝风大厦（新 ...

1 证券代码：688065 证券简称：凯赛生物 公告编号：2024-014 上海凯赛生物技术股份有限公司 2024 年第一季度业绩预告的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2024 年 1 月 1 日至 2024 年 3 月 31 日 （二）业绩预告情况 经财务部门初步核算，上海凯赛生物技术股份有限公司（以下简称"公司"） 预计 2024 年第一季度实现营业收入为 65,000 万元至 72,000 万元，与上年同期（法 定披露数据）相比，预计将增加14,455.38万元至21,455.38万元，同比增长28.60% 至 42.45%。 预计2024年第一季度实现归属于上市公司股东的净利润为9,400万元至11,500 万元，与上年同期（法定披露数据）相比，预计将增加 3,655.86 万元至 5,755.86 万元，同比增长 63.65%至 100.20%。 预计 2024 年第一季度实现归属于上市公司股东的扣除非经常性损益的净利润 为 9,100 万 ...